SI2379557T1 - Amino pirazolna spojina - Google Patents

Amino pirazolna spojina

Info

Publication number
SI2379557T1
SI2379557T1 SI200930448T SI200930448T SI2379557T1 SI 2379557 T1 SI2379557 T1 SI 2379557T1 SI 200930448 T SI200930448 T SI 200930448T SI 200930448 T SI200930448 T SI 200930448T SI 2379557 T1 SI2379557 T1 SI 2379557T1
Authority
SI
Slovenia
Prior art keywords
pyrazole compound
amino pyrazole
amino
compound
pyrazole
Prior art date
Application number
SI200930448T
Other languages
English (en)
Slovenian (sl)
Inventor
Timothy Paul Burkholder
Joshua Ryan Clayton
Liandong Ma
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41630090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2379557(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SI2379557T1 publication Critical patent/SI2379557T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200930448T 2008-12-16 2009-12-08 Amino pirazolna spojina SI2379557T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12285408P 2008-12-16 2008-12-16
PCT/US2009/067056 WO2010074947A1 (en) 2008-12-16 2009-12-08 Amino pyrazole compound
EP09795842A EP2379557B1 (en) 2008-12-16 2009-12-08 Amino pyrazole compound

Publications (1)

Publication Number Publication Date
SI2379557T1 true SI2379557T1 (sl) 2013-02-28

Family

ID=41630090

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200930448T SI2379557T1 (sl) 2008-12-16 2009-12-08 Amino pirazolna spojina

Country Status (38)

Country Link
US (2) US20100286139A1 (enExample)
EP (1) EP2379557B1 (enExample)
JP (1) JP5509217B2 (enExample)
KR (1) KR101300458B1 (enExample)
CN (1) CN102232075B (enExample)
AR (1) AR074240A1 (enExample)
AU (1) AU2009330503B2 (enExample)
BR (1) BRPI0923048A2 (enExample)
CA (1) CA2744714C (enExample)
CL (1) CL2011001445A1 (enExample)
CO (1) CO6331442A2 (enExample)
CR (1) CR20110341A (enExample)
CY (1) CY1113637T1 (enExample)
DK (1) DK2379557T3 (enExample)
DO (1) DOP2011000190A (enExample)
EA (1) EA019554B1 (enExample)
EC (1) ECSP11011132A (enExample)
ES (1) ES2396617T3 (enExample)
HN (1) HN2011001697A (enExample)
HR (1) HRP20120918T1 (enExample)
IL (1) IL213065A0 (enExample)
JO (1) JO2833B1 (enExample)
MA (1) MA32900B1 (enExample)
MX (1) MX2011006441A (enExample)
MY (1) MY158691A (enExample)
NZ (1) NZ592641A (enExample)
PA (1) PA8851101A1 (enExample)
PE (1) PE20110549A1 (enExample)
PL (1) PL2379557T3 (enExample)
PT (1) PT2379557E (enExample)
SG (1) SG172202A1 (enExample)
SI (1) SI2379557T1 (enExample)
SV (1) SV2011003949A (enExample)
TN (1) TN2011000292A1 (enExample)
TW (1) TWI440640B (enExample)
UA (1) UA104743C2 (enExample)
WO (1) WO2010074947A1 (enExample)
ZA (1) ZA201103942B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2435646A (en) * 2006-03-01 2007-09-05 Spin Tec Engineering Gmbh Apparatus and method of extraction of an arthropod gland
US8105633B2 (en) * 2006-03-01 2012-01-31 Spintec Engineering Gmbh Method and apparatus for extraction of arthropod gland
US20110121485A1 (en) * 2006-10-30 2011-05-26 Spintec Engineering Gmbh Method and apparatus for the manufacture of a fiber
KR20130131461A (ko) * 2011-03-07 2013-12-03 폰다지오네 텔레톤 Tfeb 변종 및 그의 용도
PH12013502530A1 (en) * 2011-06-15 2014-01-27 Life And Brain Gmbh Glioblastoma inhibiting compounds and their use
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
PL400213A1 (pl) 2012-08-01 2014-02-03 Celon Pharma Spólka Z Ograniczona Odpowiedzialnoscia Pochodne imidazo[1,2-b]pirydazyno-6-aminy jako inhibitory kinazy JAK-2
RS63364B1 (sr) 2014-08-11 2022-07-29 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
SMT202100674T1 (it) 2014-08-11 2022-01-10 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2
US11299494B2 (en) * 2016-11-17 2022-04-12 Bristol-Myers Squibb Company Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN110305140B (zh) 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
CA2467718C (en) 2001-12-21 2011-04-26 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
KR20070104936A (ko) 2005-02-16 2007-10-29 아스트라제네카 아베 화합물
KR101362621B1 (ko) 2005-02-16 2014-02-13 아스트라제네카 아베 화합물
BRPI0613501A2 (pt) * 2005-07-01 2011-01-11 Irm Llc composto, composição farmacêutica e uso do mesmo
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
PE20070543A1 (es) * 2005-10-06 2007-06-14 Schering Corp Pirazolopirimidinas como inhibidores de protein quinasas
CN101321759A (zh) * 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶化合物
US7728017B2 (en) 2005-11-30 2010-06-01 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
CN101594909A (zh) 2006-09-07 2009-12-02 比奥根艾迪克Ma公司 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
BRPI0718266A2 (pt) * 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
CN101679429A (zh) * 2007-04-18 2010-03-24 阿斯利康(瑞典)有限公司 5-氨基吡唑-3-基-3h-咪唑并[4,5-b]吡啶衍生物及其治疗癌的用途
MX2009012612A (es) 2007-05-23 2009-12-07 Pharmacopeia Llc Purinonas e inhibidores 1h-imidazopiridinonas como pkc-theta.
WO2009062059A2 (en) 2007-11-08 2009-05-14 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors

Also Published As

Publication number Publication date
AU2009330503B2 (en) 2012-06-07
US20100152181A1 (en) 2010-06-17
EP2379557A1 (en) 2011-10-26
HN2011001697A (es) 2013-11-26
AR074240A1 (es) 2011-01-05
CO6331442A2 (es) 2011-10-20
PT2379557E (pt) 2013-01-14
MY158691A (en) 2016-10-31
PL2379557T3 (pl) 2013-03-29
EP2379557B1 (en) 2012-10-31
KR101300458B1 (ko) 2013-08-30
HRP20120918T1 (hr) 2012-12-31
CY1113637T1 (el) 2016-06-22
WO2010074947A1 (en) 2010-07-01
MA32900B1 (fr) 2011-12-01
SV2011003949A (es) 2011-07-21
PA8851101A1 (es) 2010-07-27
ZA201103942B (en) 2012-08-29
EA019554B1 (ru) 2014-04-30
HK1160109A1 (en) 2012-08-10
CR20110341A (es) 2011-07-13
MX2011006441A (es) 2011-07-19
DOP2011000190A (es) 2011-07-31
CL2011001445A1 (es) 2011-11-11
US7897600B2 (en) 2011-03-01
CN102232075B (zh) 2013-12-11
DK2379557T3 (da) 2012-12-17
CA2744714A1 (en) 2010-07-01
PE20110549A1 (es) 2011-08-04
ECSP11011132A (es) 2011-07-29
CN102232075A (zh) 2011-11-02
JP5509217B2 (ja) 2014-06-04
TN2011000292A1 (en) 2012-12-17
TWI440640B (zh) 2014-06-11
AU2009330503A1 (en) 2010-07-01
KR20110084993A (ko) 2011-07-26
SG172202A1 (en) 2011-07-28
ES2396617T3 (es) 2013-02-22
BRPI0923048A2 (pt) 2018-09-25
JO2833B1 (en) 2014-09-15
CA2744714C (en) 2013-06-25
US20100286139A1 (en) 2010-11-11
JP2012512158A (ja) 2012-05-31
TW201024301A (en) 2010-07-01
IL213065A0 (en) 2011-07-31
UA104743C2 (ru) 2014-03-11
NZ592641A (en) 2013-01-25
EA201170831A1 (ru) 2011-12-30

Similar Documents

Publication Publication Date Title
IL213065A0 (en) Amino pyrazole compound
ZA201007686B (en) Amide compound
IL210082A0 (en) Pyrazole compounds 436
ZA201006511B (en) Heterocyclic compound
PT1999114E (pt) Pirazóis como 11-beta-hds-1
EP2166849A4 (en) SUBSTITUTED PYRAZOL COMPOUNDS
ZA201100139B (en) Azole compound
GB0804989D0 (en) Compound
EP2373313A4 (en) SUBSTITUTED PYRAZOL COMPOUNDS
GB0803494D0 (en) Compound
EP2235089A4 (en) POLYAMIDE
IL207035A0 (en) Benzylpiperizine compound
IL215235A0 (en) Pyrazole compound
ZA201102450B (en) Amino acid derivative
EP2345644A4 (en) INDAZOLE COMPOUND
GB0823316D0 (en) Compound
GB0806744D0 (en) Novel pyrazole derivatives
GB0807160D0 (en) Compound
GB0806005D0 (en) Compound
GB0820249D0 (en) Compound
GB0822635D0 (en) Compound
GB0820919D0 (en) Compound
GB0820918D0 (en) Compound
GB0805430D0 (en) Compound
GB0802193D0 (en) Compound